Coiled-coil-helix-coiled-coil-helix domain-containing 3 (CHCHD3)

Coiled-coil-helix-coiled-coil-helix domain-containing 3 (CHCHD3), also known as MIC19, is a critical subunit of the Mitochondrial contact site and cristae organizing system (MICOS) complex located in the inner mitochondrial membrane (UniProt Q9NX63). It acts as a peripheral membrane protein that bridges the MICOS complex to the outer membrane via interactions with SAMM50, ensuring the stability of crista junctions and the maintenance of mitochondrial architecture (PubMed: 22114354). By maintaining the characteristic folding of the inner membrane, CHCHD3 is essential for efficient oxidative phosphorylation and the compartmentalization of mitochondrial biochemical reactions (PubMed: 25785304). Dysfunction or depletion of CHCHD3 leads to profound alterations in mitochondrial morphology, including the loss of cristae and fragmented mitochondria, which are hallmark features of various mitochondrial myopathies and neurodegenerative disorders such as Parkinson's disease (PubMed: 26506309). While it is currently considered a difficult pharmacological target due to its structural role and intramitochondrial localization, it represents a significant point of interest for therapeutic strategies aimed at restoring mitochondrial health in metabolic and age-related diseases. There are currently no small molecules or biologics in clinical development specifically targeting CHCHD3, but it remains a vital biomarker for assessing mitochondrial structural integrity in preclinical research.

Other names

MIC19MINOS3Mitochondrial inner membrane organizing system 3MICOS complex subunit MIC19

Currently no clinical drugs target this protein; hypothetical mechanisms involve stabilizing the MICOS complex to restore mitochondrial cristae architecture and metabolic efficiency.